Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Oxcarbazepine Tablet Study design [Design Issues]

posted by jag009 – NJ, 2024-07-23 21:50 (53 d 00:15 ago) – Posting: # 24094
Views: 945

Hi,

What is your CV for AUC? Like Helmut wrote, Canada requires T/R ratio for Cmax, not 90% CI. Therefore you just need to design and power your study based on CV for AUC.
J

Complete thread:

Oxcarbazepine Tablet Study design AB661 2024-07-13 09:02 [Design Issues]
- ABE or ABEL for Health Canada Helmut 2024-07-14 12:17
- Oxcarbazepine Tablet Study designjag009 2024-07-23 19:50
  - Health Canada ABEL Helmut 2024-07-24 09:06
  - Oxcarbazepine Tablet Study design AB661 2024-08-24 11:00
    - Oxcarbazepine Tablet Study design Helmut 2024-08-24 12:19

Admin contact
23,224 posts in 4,878 threads, 1,652 registered users;
41 visitors (0 registered, 41 guests [including 11 identified bots]).
Forum time: 22:05 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty. Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz